36 results about "Benzylisoquinoline" patented technology

Host cells that are engineered to produce benzylisoquinoline alkaloid (BIAs) precursors, such as norcoclaurine (NC) and norlaudanosoline (NL), are provided. The host cells may have one or more engineered modifications selected from: a feedback inhibition alleviating mutation in a enzyme gene; a transcriptional modulation modification of a biosynthetic enzyme gene; an inactivating mutation in an enzyme; and a heterologous coding sequence. Also provided are methods of producing a BIA of interest or a precursor thereof using the host cells and compositions, e.g., kits, systems etc., that find use in methods of the invention.

The invention discloses a sulfonyl fangchinoline compound as well as a preparation method and application thereof. The sulfonyl fangchinoline compound has a structure as shown in a formula (I) or a formula (I'). According to the formula (I) or formula (I'), R is selected from alkyl, aryl, benzyl, heterocyclyl, substituted alkyl, substituted aryl, substituted benzyl and substituted heterocyclyl; the substituent group of the substituted alkyl is halogen or nitro; the substituent group of the substituted aryl, the substituent group of the substituted benzyl and the substituent group of the substituted heterocyclyl are one or more of halogen, alkyl and nitro; Y is selected from one-molecule inorganic acid and organic acid or two-molecule inorganic acid and organic acid. The compound has a bisbenzylisoquinoline parent nucleus structure, has sulfonyl characteristics, has a good XOD inhibition effect, and can be used for treating and improving gout, reducing uric acid and the like.

The invention discloses bisbenzylisoquinoline betaine with anti-tumor activity and a preparation method thereof. The compound has the following structural general formula shown in the specification. The preparation method comprises the steps of taking bisbenzylisoquinoline compounds as raw materials, dissolving into a certain solvent, adding a catalyst and a reactant Y, mixing, performing reaction for 0.1-72 hours at -20 DEG C to 300 DEG C, performing hydrolysis and neutralization reaction on the materials after reaction, and then separating and purifying to obtain an objective product. According to the preparation method disclosed by the invention, the prepared bisbenzylisoquinoline betaine has a relatively good inhibiting effect on proliferation of the human liver cancer cell strain HepG2 and leukemia K562 cells, and can be used for preparing anti-tumor medicaments.

The invention provides a mivacurium chloride hydrate including mivacurium chloride hydrate I and mivacurium chloride hydrate II, and a preparation method and use thereof. The water content of the mivacurium chloride hydrate I is 2.90-3.35 wt%. The mivacurium chloride hydrate disclosed by the invention is good in stability under the conditions of high temperature, high humidity, illumination and acceleration tests; the moisture content is not obviously increased under the condition of a hygroscopicity test, and the product can be stably stored for a long time; and in addition, the preparation process is simple, no special equipment requirement is required, the product is high in yield and purity, the reproducibility is good and the product is suitable for industrial production.

The invention relates to bisbenzylisoquinoline glycine betaines as well as a preparation method thereof and an application in preparing anti-tumor medicines. The structural formula of the bisbenzylisoquinoline glycine betaines is as shown in a general formula (I); substituent groups in the formula are as shown in the specification; the bisbenzylisoquinoline glycine betaines are obtained by reacting bisbenzylisoquinoline or substitutes with a halogenated fatty acid salt in a solvent at a temperature ranging from minus 20 to 300 DEG C. The chemical structural of the bisbenzylisoquinoline glycine betaines enables the affinity to a receptor to be enhanced, and the bisbenzylisoquinoline glycine betaines have relatively high inhibition activity on the proliferation of the human hepatocarcinoma cell line HepG2 and the human colon cancer cells HT29. The anti-liver cancer activity of the bisbenzylisoquinoline glycine betaines is more than 20 times higher than that of the existing tetrandrine compounds, and therefore, the clinical dosage of the medicines can be reduced so that the toxic and side effects of the medicines can be reduced. The general formula is as shown in the specification. The general formula (I) is as shown in the specification.

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (BIAs) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as thebaine and morphine and their derivatives. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and/or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthases and polynucleotides encoding the same, are provided. Further, methods of adjusting pH to optimize the reaction are disclosed.

The invention relates to a class of benzyl isoquinoline compounds, a preparation method and application thereof, wherein the structure of the compound is represented by a formula I. The stereoisomer with the structure represented by the formula (I) or the stereoisomer mixture or the pharmaceutically acceptable salt, the solvate of the stereoisomer or the stereoisomer mixture, and the pharmaceutical composition formed by the stereoisomer or the stereoisomer mixture and the pharmaceutically acceptable carrier can generate a neuromuscular junction retardation effect and are applied to the field of preparation of muscle relaxation drugs. Each substituent is consistent with that in the specification.

The invention discloses an application of an Ac6OMT gene in production of benzylisoquinoline alkaloid and a derivative thereof. The nucleotide sequence of the Ac6OMT gene is as shown in SEQ ID NO. 1; and the synthesized amino acid sequence is as shown in SEQ ID NO. 2. The invention further discloses application of the Ac6OMT gene in breeding transgenic plant varieties which are synthesized or cannot be synthesized with the benzylisoquinoline alkaloid and the derivative thereof, and records a method for regulating organisms to synthesize the benzylisoquinoline alkaloid and the derivative thereof. The Ac6OMT coding gene in a synthetic pathway of the benzylisoquinoline alkaloid and derivatives thereof is subjected to functional identification, and the gene can be applied to biosynthesis and molecular breeding of the aristolochia contorta benzylisoquinoline alkaloid.